# EDGAR Filing Document

**Accession Number:** 0001417926
**File Stem:** 0001493152-25-015821
**Filing Date:** 2025-9
**Character Count:** 15607
**Document Hash:** a62e613f51bb55be3239c808e9671368
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-015821.hdr.sgml**: 20250926

**ACCESSION NUMBER**: 0001493152-25-015821

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250922

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250926

**DATE AS OF CHANGE**: 20250926

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INVO Fertility, Inc.
- **CENTRAL INDEX KEY:** 0001417926
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 204036208
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39701
- **FILM NUMBER:** 251351597

**BUSINESS ADDRESS:**
- **STREET 1:** 5582 BROADCAST COURT
- **CITY:** SARASOTA
- **STATE:** FL
- **ZIP:** 34240
- **BUSINESS PHONE:** (978) 878-9505

**MAIL ADDRESS:**
- **STREET 1:** 5582 BROADCAST COURT
- **CITY:** SARASOTA
- **STATE:** FL
- **ZIP:** 34240

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NAYA Biosciences, Inc.
- **DATE OF NAME CHANGE:** 20241022

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INVO Bioscience, Inc.
- **DATE OF NAME CHANGE:** 20090106

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EMY'S SALSA AJI DISTRIBUTION COMPANY, INC.
- **DATE OF NAME CHANGE:** 20071108

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **September 22, 2025**

**INVO FERTILITY, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-39701** | **20-4036208** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

**5582 Broadcast Court**

**Sarasota, FL 34240**

(Address of principal executive offices, including zip code)

(978) 878-9505

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value | IVF | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry Into Material Definitive Agreement.**

*Decathlon Amendment*

On September 29, 2023, the Company, its CEO, Steven Shum as a Key Person (as defined in the Loan Agreement – defined below), and the Company's wholly-owned subsidiaries Bio X Cell, Inc, INVO Centers LLC, Wood Violet, Fertility Labs of Wisconsin LLC and Orange Blossom Fertility LLC as guarantors (the "Guarantors"), entered into a Revenue Loan and Security Agreement (the "Loan Agreement") with Decathlon Alpha V LP (the "Lender") under which the Lender advanced a gross amount of $1,500,000 to the Company.

The foregoing summary of the Loan Agreement is not complete and is qualified in its entirety by reference to the Loan Agreement, a copy of which was filed as Exhibit 10.1 to a Current Report on Form 8-K filed on October 5, 2023 and is incorporated herein by reference.

On September 24, 2024, the Company, the Lender, Steven Shum and the Guarantors entered into an amendment to the Loan Agreement (the "First Amendment"), pursuant to which (i) the Lender approved that certain Standard Merchant Cash Advance Agreement, dated September 25, 2024 between the Company and Cedar Advance LLC, and (ii) the Company agreed to increase the "Minimum Interest" (as defined in the Loan Agreement) multiples set forth therein by 0.15 effective as of December 1, 2024, if the Company did not receive equity investment of at least $1,000,000 by November 30, 2024.

The foregoing summary of the First Amendment is not complete and is qualified in its entirety by reference to the Loan Agreement, a copy of which was filed as Exhibit 10.2 to a Current Report on Form 8-K filed on October 1, 2024 and is incorporated herein by reference.

On October 11, 2024, the Company, the Lender, Steven Shum and the Guarantors entered into a second amendment to the Loan Agreement (the "Second Amendment"), pursuant to which The Company agreed, among other things, to pay down its loan by at least $500,000 and increase its monthly payments by up to $30,000 if the Company closes a private offering of its securities. The Company also agreed to retain an investment banker to pursue a financing or a sale if it fails to meet certain liquidity covenants.

The foregoing summary of the Loan Agreement is not complete and is qualified in its entirety by reference to the Second Amendment, a copy of which was filed as Exhibit 10.3 to a Current Report on Form 8-K filed on October 15, 2024 and is incorporated herein by reference.

On August 13, 2025, the Company, the Lender, Steven Shum and the Guarantors entered into a third amendment to the Loan Agreement (the "Third Amendment"), pursuant to which (a) the Lender consented to the change of the Company's name to INVO Fertility, Inc., (b) the Lender waived the event of default that would result from the entry of judgment pursuant to the Term Sheet with Dr. Pritts and the Pritts Trust, (c) the parties agreed to an adjusted repayment schedule whereby the monthly payment under the Loan Agreement increased by $20,000, and (d) the Company agreed to reimburse the Lender for approximately $17,500 in fees and expenses incurred in connection with the Third Amendment.

The foregoing summary of the Third Amendment is not complete and is qualified in its entirety by reference to the Third Amendment, a copy of which was filed as Exhibit 10.1 to the Quarterly Report on Form 10-Q filed on August 14, 2025 and is incorporated herein by reference.

On September 22, 2025, the Company, the Lender, Steven Shum, and the Guarantors entered into a restated third amendment to the Loan Agreement (the "Restated Third Amendment"), pursuant to which and in addition to amendments set forth in the Third Amendment, since the Company did not raise the above stated $1 million by November 30, 2024 as required under the Loan Agreement, the Loan Agreement was amended to reflect an increase of 0.15 the Minimum Interest multiples set forth in the Loan Agreement.

The foregoing summary of the Loan Agreement is not complete and is qualified in its entirety by reference to the Loan Agreement, copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Restated Third Amendment to Revenue Loan and Security Agreement](ex10-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document.) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Date: September 26, 2025 | **INVO FERTILITY, INC.** |
|  | */s/ Steven Shum* |
|  | Steven Shum |
|  | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**RESTATED THIRD AMENDMENT TO REVENUE LOAN AND SECURITY AGREEMENT**

This restated third amendment (this "**Amendment**") to that certain Revenue Loan and Security Agreement dated September 29, 2023, as amended by Amended and Restated First Amendment dated September 24, 2024 and Second Amendment dated October 11, 2024 (as amended, the "**Agreement**"), by and among Steven Shum ("**Key Person**"), INVO Fertility, Inc., a Nevada corporation f/k/a NAYA Biosciences, Inc. and f/k/a INVO Bioscience Inc. (the "**Company**"), the Guarantors identified on the signature page hereto (the "**Guarantors**"), and Decathlon Alpha V, L.P., a Delaware limited partnership ("**Lender**"), is dated August 11, 2025 (the "**Third Amendment Date**"). Unless otherwise defined herein, all capitalized terms have the meanings given to them in the Agreement.

The Company has requested that Lender consent to an amendment to the Company's name to INVO Fertility, Inc. and consent to the entry by the Company, INVO Centers LLC, Wisconsin Fertility and Reproductive Surgery Associates, S.C., and Wood Violet Fertility LLC into a settlement agreement with Dr. Elizabeth Pritts, which includes the entry of a consent judgment against the Company, INVO Centers LLC, Wisconsin Fertility and Reproductive Surgery Associates, S.C., and Wood Violet Fertility LLC, according to the terms of a term sheet executed May 14, 2025 (the "**Pritts Settlement**").

In connection with and as a material inducement to Lender to make accommodations with respect to these requests, the Company desires to make amendments to the Agreement as provided herein.

The Company, the Key Person, the Guarantors and Lender hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1. Effectiveness of Amendment**. This Amendment will be effective upon Lender's receipt of the transaction costs identified in <u>Section 5</u>, below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2. Consent to Name Change**. Pursuant to <u>Section 5.10</u> of the Agreement, Lender hereby consents to the change of Company's name to INVO Fertility, Inc.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3. Waiver as to Pritts Settlement**. Lender hereby waives the Event of Default that results pursuant to <u>Section 7.4</u> of the Agreement from the entry of a judgment for the payment of money in excess of $50,000 as a result of the Pritts Settlement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4. Amendments**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1. **Schedule 2.3(b)(2)**. An amended and restated <u>Schedule 2.3(b)(2)</u> to the Agreement is attached hereto as <u>Schedule 2.3(b)(2)</u>. For the sake of clarity, the monthly payment due on each Payment Date, which is set forth in the column labeled "Projected Payment" on <u>Schedule 2.3(b)(2)</u>, is increasing by $20,000 beginning in August 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2. **Schedule 11.3**. The Company acknowledges and agrees that the Minimum Interest multiples on <u>Schedule 11.3</u> to the Agreement increased by 0.15 as of December 1, 2024 due to the Company's failure to receive equity investments during the period between the Amended and Restated First Amendment Date and November 30, 2024 in the net amount of $1,000,000, pursuant to <u>Section 1.3</u> of the Amended and Restated First Amendment. To reflect the increase in Minimum Interest multiples and memorialize the effect of <u>Section 1.3</u> of the Amended and Restated First Amendment, an amended and restated <u>Schedule 11.3</u> to the Agreement is attached hereto as <u>Schedule 11.3</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5. Transaction Costs**. Pursuant to <u>Section 12.7</u> of the Agreement, Company will reimburse Lender for all fees and expenses incurred by Lender relating to the First Amendment, the Second Amendment, this Amendment, the Pritts Settlement, and the Loan Agreement. Without limiting the foregoing, Company shall pay Lender $17,488 related to Lender's fees and expenses incurred in connection herewith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6. No Other Changes**. In all other respects, the Agreement shall remain in full force and effect.

*\*\* Signatures on following page \*\**

 

The parties have executed this Amendment on September 22, 2025 but to be effective as of the Third Amendment Date.

**COMPANY:**

INVO FERTILITY, INC., a Nevada corporation f/k/a NAYA BIOSCIENCES, INC. f/k/a INVO BIOSCIENCE, INC.

---

| | |
|:---|:---|
| By: | /s/ Steven Shum |
|  | Steven Shum, CEO |

---

---

| | |
|:---|:---|
| **LENDER:** | **LENDER:** |
| DECATHLON ALPHA V, L.P. | DECATHLON ALPHA V, L.P. |
| By: | Decathlon Alpha GP V, LLC |
| Its: | General Partner |

---

---

| | |
|:---|:---|
| By: | /s/ John Borchers |
|  | John Borchers, Managing Director |

---

---

| | |
|:---|:---|
| **KEY PERSON:** | **KEY PERSON:** |
| By: | /s/ Steven Shum |
|  | Steven Shum |

---

**GUARANTORS:**

BIO X CELL INC

---

| | |
|:---|:---|
| By: | /s/ Steven Shum |
|  | Steve Shum, President |

---

---

| | |
|:---|:---|
| INVO CENTERS LLC | INVO CENTERS LLC |
| By: | /s/ Steven Shum |
|  | Steve Shum, Managing Member |

---

---

| | |
|:---|:---|
| WOOD VIOLET FERTILITY LLC | WOOD VIOLET FERTILITY LLC |
| By: | /s/ Steven Shum |
|  | Steve Shum, Managing Member |

---

---

| | |
|:---|:---|
| FERTILITY LABS OF WISCONSIN LLC | FERTILITY LABS OF WISCONSIN LLC |
| By: | /s/ Steven Shum |
|  | Steve Shum, Managing Member |

---

---

| | |
|:---|:---|
| ORANGE BLOSSOM FERTILITY LLC | ORANGE BLOSSOM FERTILITY LLC |
| By: | /s/ Steven Shum |
|  | Steve Shum, Managing Member |

---

**SCHEDULE 2.3(b)(2)**

![](ex10-1_001.jpg)

**SCHEDULE 11.3**

**MINIMUM INTEREST**

The "**Minimum Interest**" means the amount shown below in the column headed Minimum Interest opposite the applicable period during which the Payoff Date occurs:

---

| | |
|:---|:---|
| **Period During Which the Payoff Date Occurs** | **Minimum Interest** |
| On or before 6 months after the Effective Date | 0.35 times the Amount Advanced |
| After 6 months and on or before 12 months after the Effective Date | 0.50 times the Amount Advanced |
| After 12 months and on or before 18 months after the Effective Date | 0.85 times the Amount Advanced |
| After 18 months and on or before 24 months after the Effective Date | 0.95 times the Amount Advanced |
| After 24 months and on or before 30 months after the Effective Date | 1.05 times the Amount Advanced |
| After 30 months after the Effective Date | 1.15 times the Amount Advanced |

---